In another report (86), we have shown that RA patients with robust responses to anti-TNF therapies are characterized at baseline by immune pathway activation involving lymphocytes, memory B cells, and plasmablasts; and that these pathways were inhibited by anti-TNF treatment both at the synovial gene expression and peripheral proteins levels. Here, TNF is linked to rheumatoid arthritis.